- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Isolated hepatic perfusion.
Displaying page 1 of 1.
EudraCT Number: 2013-000564-29 | Sponsor Protocol Number: SUGBG-013001 | Start Date*: 2013-04-25 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases | ||
Medical condition: Uveal melanoma liver metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005088-25 | Sponsor Protocol Number: 01234 | Start Date*: 2006-11-15 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases. | ||
Medical condition: Patients with isolated hepatic metastases of histologically confirmed colorectal adenocarcinoma and for the phase I study also isolated hepatic metastases of all other solid tumors. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003188-24 | Sponsor Protocol Number: CA184-587 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases | |||||||||||||
Medical condition: Metastatic uveal melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001956-31 | Sponsor Protocol Number: 2015-001956-31 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre. | |||||||||||||
Full Title: Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants | |||||||||||||
Medical condition: Patients with chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000307-32 | Sponsor Protocol Number: 20110264 | Start Date*: 2014-11-18 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Me... | ||
Medical condition: Unresected, Stage IIIB-IV Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
